UCB Valuation
Is UNC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of UNC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: UNC (CHF77.91) is trading below our estimate of fair value (CHF146.37)
Significantly Below Fair Value: UNC is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UNC?
Key metric: As UNC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is UNC's PE Ratio? | |
|---|---|
| PE Ratio | 38.8x |
| Earnings | €420.00m |
| Market Cap | €16.31b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.4x |
| Enterprise Value/EBITDA | 16.1x |
| PEG Ratio | 1.6x |
Price to Earnings Ratio vs Peers
How does UNC's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 23.2x | ||
DESN Dottikon ES Holding | 39.9x | n/a | CHF 3.2b |
NOVN Novartis | 18x | 7.0% | CHF 186.5b |
ROG Roche Holding | 19.2x | 11.2% | CHF 205.2b |
COPN Cosmo Pharmaceuticals | 15.7x | 17.2% | CHF 1.0b |
UNC UCB | 38.8x | 24.8% | CHF 16.3b |
Price-To-Earnings vs Peers: UNC is good value based on its Price-To-Earnings Ratio (38.8x) compared to the peer average (42.6x).
Price to Earnings Ratio vs Industry
How does UNC's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: UNC is expensive based on its Price-To-Earnings Ratio (38.8x) compared to the European Pharmaceuticals industry average (21.6x).
Price to Earnings Ratio vs Fair Ratio
What is UNC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 38.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate UNC's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Roche Holding
CHF 205.2b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.
RO
CHF 270.80
7D
0.4%
1Y
7.0%
Gerresheimer
€2.6b
Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.
GXI
€75.60
7D
0%
1Y
0%
Bristol-Myers Squibb
US$100.3b
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
BMY
US$54.24
7D
0%
1Y
0%